Victoza for People with Type 1 Diabetes? (Continued)
dLife Editor's note —
diaTribe Editor Kelly Close's column received a great response from her readers and she reprinted the column in November 2010 with the following additional information:
Someone asked me how I use Symlin in my diabetes regimen that includes a daily shot of Victoza. While initially I stopped using Symlin for a little while, I'm now using it again, with insulin and Victoza — not before every meal, but definitely before all my high-carb meals. My sense is that as a patient with diabetes, I am probably missing multiple important hormones. Symlin works very well for me in lowering my post-meal blood glucose levels and when I'm eating pizza or a sandwich or fettucini, I still take Symlin to reduce these numbers — and it does. I am eager to eventually try an insulin/Symlin combo, since I have heard from so many people that Symlin works best in a pump — here's hoping that will be developed soon. (I tried Symlin in an extra pump myself and loved it and only quit because my insurance didn't reimburse the extra pods — I'd rather wear one pump and have the combined insulin/Symlin to take, if this could be created in a formulation that worked for many people.)
Novo Nordisk then issued their own response:
We read the diaTribe article describing your recent experience using Victoza as an adjunct to insulin to treat your type 1 diabetes. We are happy to hear that Victoza has lowered your mean glucose levels and also has resulted in a decrease in the frequency of both high and low glucose levels.
Our development program established a strong foundation for the use of Victoza as monotherapy or in combination with one or two oral agents in type 2 diabetes. As you pointed out, Victoza has not yet been studied in or approved for the treatment of type 1 diabetes, and it is not a substitute for insulin. However, your personal experience provides one of many reasons why Novo Nordisk is currently considering exploring the use of Victoza for type 1 diabetes in well-designed, controlled, randomized clinical trials. While we can not guarantee the time course or the outcome, we are carefully evaluating the possibilities for launching such a program.
Thank you for making us aware of your experience and for sharing so many insights about living with diabetes.
Alan C. Moses, MD, FACP
Global Chief Medical Officer
Novo Nordisk A/S
Mads Krosgard Thomsen
Chief Scientific Officer
Novo Nordisk A/S
diaTribe is an independent, advertising-free e-newsletter for everyone eager to learn about the latest advances in diabetes management. diaTribe is your inside track on diabetes research and products — sign up here for your complimentary lifetime subscription!
NOTE: This information is not intended to be a replacement or substitute for consultation with a qualified medical professional or for professional advice related to diabetes or another medical condition. Please contact your physician or medical professional with any questions and concerns about your medical condition.
Tomato Soup with Veggies Salmon with Watercress Puree Cottage Cheese Parfaits Potato and Pepper Kabobs Speedy Chili Mashed Eggplant Salad Caramelized Pork over Herbed Lettuce Grilled Sirloin with Caper Mustard Sauce Three Kings Colorful Quesadillas Lentil Salad with Vegetables
As I mentioned in an earlier post, one of the benefits that made it cost-effective for me to go with the real healthcare (HSA) plan rather than the phony (HRA) plan is that my company is now covering "preventative" medicines at $0 copay. The formulary for these, as stated by CVS/Caremark (my pharmacy benefits provider), covers all test strips, lancets, and control solutions. I dutifully get my doctor to write up prescriptions for all of my testing needs, submit...